IDO, which was developed as a key negative controller of anti-tumor T lymphocytes [3], is upregulated in response to activated T lymphocytes [4], and promotes the development of FoxP3+ regulatory T lymphocytes [5]. The gene discussed is IDO1; the disease is neoplasm.